EHHADH: A Potential Drug Target and Biomarker (G1962)

Target Name: EHHADH

NCBI ID: G1962

EHHADH

EHHADH: A Potential Drug Target and Biomarker

Erythropoietin (ESP) is a hormone produced by the liver that is responsible for the production of red blood cells (RBCs) in the human body. It is a critical hormone that helps maintain the health and function of the immune system. However, in some individuals with certain genetic disorders, the production of ESP is reduced, leading to anemia and other complications. Erythropoietin deficiency is a serious medical condition that can cause serious health complications, including infection, heart failure, and even death.

Recent studies have identified that EHHADH, a gene that encodes the Erythropoietin receptor, may be a potential drug target for the treatment of anemia and other disorders related to Erythropoietin deficiency. In this article, we will discuss the potential benefits of targeting EHHADH and the research that has been done to investigate its potential as a drug target.

The Erythropoietin Receptor

The Erythropoietin receptor is a protein that is expressed in the liver and other tissues. It is responsible for interacting with Erythropoietin, a hormone that is produced by the liver to regulate the production of red blood cells. The Erythropoietin receptor plays a crucial role in maintaining the health and function of the immune system, as it helps to regulate the production of red blood cells that are responsible for carrying oxygen throughout the body.

EHHADH Mutation and Anemia

Erythropoietin deficiency is a serious medical condition that can cause anemia and other complications. In some individuals with this condition, the production of ESP is reduced, leading to anemia. This can have serious consequences for an individual's overall health and quality of life.

Recent studies have identified that EHHADH, a gene that encodes the Erythropoietin receptor, may be a potential drug target for the treatment of anemia and other disorders related to Erythropoietin deficiency. The EHHADH gene has been shown to be associated with anemia in individuals with Erythropoietin deficiency.

Targeting EHHADH

Targeting EHHADH as a drug target has the potential to treat anemia and other disorders related to Erythropoietin deficiency. This can be achieved by using drugs that target the EHHADH receptor, which can help to increase the production of Erythropoietin in the liver.

One of the potential benefits of targeting EHHADH is that it can help to increase the production of Erythropoietin in the liver, which can help to treat anemia. This can be achieved by using drugs that target the EHHADH receptor and help to stimulate the production of Erythropoietin.

Another potential benefit of targeting EHHADH is that it can help to reduce the production of Erythropoietin in the liver, which can be useful in treating anemia in individuals with this condition. This can be achieved by using drugs that target the EHHADH receptor and help to reduce the production of Erythropoietin in the liver.

EHHADH as a Biomarker

EHHADH has also been shown to be a potential biomarker for Erythropoietin deficiency. This can be achieved by using techniques such as mass spectrometry, which allows researchers to detect and measure the expression of specific genes in the liver. Studies have shown that EHHADH is expressed in the liver and other tissues, and that it is involved in the production of Erythropoietin.

Conclusion

In conclusion, EHHADH is a gene that encodes the Erythropoietin receptor, a protein that is responsible for interacting with Erythropoietin, a hormone that is produced by the liver to regulate the production of red blood cells. Studies have shown that EHHADH is associated with anemia in individuals with Erythropoietin deficiency, and that it has the potential to be a drug target for the treatment of this condition. Targeting EHHADH with drugs that

Protein Name: Enoyl-CoA Hydratase And 3-hydroxyacyl CoA Dehydrogenase

Functions: Peroxisomal trifunctional enzyme possessing 2-enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase, and delta 3, delta 2-enoyl-CoA isomerase activities. Catalyzes two of the four reactions of the long chain fatty acids peroxisomal beta-oxidation pathway (By similarity). Can also use branched-chain fatty acids such as 2-methyl-2E-butenoyl-CoA as a substrate, which is hydrated into (2S,3S)-3-hydroxy-2-methylbutanoyl-CoA (By similarity). Optimal isomerase for 2,5 double bonds into 3,5 form isomerization in a range of enoyl-CoA species (Probable). Also able to isomerize both 3-cis and 3-trans double bonds into the 2-trans form in a range of enoyl-CoA species (By similarity). With HSD17B4, catalyzes the hydration of trans-2-enoyl-CoA and the dehydrogenation of 3-hydroxyacyl-CoA, but with opposite chiral specificity (PubMed:15060085). Regulates the amount of medium-chain dicarboxylic fatty acids which are essential regulators of all fatty acid oxidation pathways (By similarity). Also involved in the degradation of long-chain dicarboxylic acids through peroxisomal beta-oxidation (PubMed:15060085)

The "EHHADH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EHHADH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets